EUVIMEDEUVIMED entdecken
Crossref

The Discovery of GS-1291269: A Neutral Ketohexokinase (KHK) Inhibitor with an Unusual Thietane Amine Functional Group

Zachary A Kasun iD, Xiaomin Liang, Ryan D Ferrao, Joshua A Kaplan, Christopher T Clark, Megan E Neubig, Daniel H Byun, Shawn S Badal, Natalie Sroda, Tina Mistry, Nathaniel H Stanley iD, Kirk L Stevens und 8 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Zachary A Kasun und 19 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California 94404, United States. Hauptthemen laut MEDLINE: Fructokinases, Enzyme Inhibitors, Amines, Drug Discovery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ketohexokinase (KHK) is the primary enzyme involved in fructose metabolism, converting fructose to fructose-1-phosphate (F1P). KHK is implicated in diseases, including metabolic-dysfunction-associated steatotic liver disease (MASLD) and diabetic kidney disease (DKD), among others. Herein, we describe the discovery of GS-1291269, a potent, neutral KHK inhibitor. GS-1291269 has pharmacokinetic parameters in preclinical species that support once-daily dosing in humans. The high potency and favorable PK profile of GS-1291269 can be attributed to the uncommon dioxo-thietane amine functional group, which avoids potential PK liabilities associated with acidic or basic molecules yet provides a hydrogen bond donor that is critical for potency. Furthermore, GS-1291269 demonstrated liver and kidney fructose-1-phosphate (F1P) reduction in a fructose challenge model in rats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FructokinasesEnzyme InhibitorsAminesDrug DiscoveryAnimalsHumansRatsStructure-Activity RelationshipMaleRats, Sprague-Dawley

Substanzen

ketohexokinaseFructokinasesEnzyme InhibitorsAmines

Autor:innen und Institutionen

  • Gilead Sciences, Inc., Foster City, California 94404, United States.

ORCID-Profile: Zachary A Kasun, Nathaniel H Stanley

Förderung

  • Gilead Sciences

Zitieren

APA

Kasun, Z. A., Liang, X., Ferrao, R. D., Kaplan, J. A., Clark, C. T., Neubig, M. E., Byun, D. H., Badal, S. S., Sroda, N., Mistry, T., Stanley, N. H., Stevens, K. L., Bachman, J. L., Lo, J. R., Loyer-Drew, J., Velasquez, M., Hao, J., Mwangi, J., Stafford, B., & Jansa, P. (2025). The Discovery of GS-1291269: A Neutral Ketohexokinase (KHK) Inhibitor with an Unusual Thietane Amine Functional Group. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02896

Vancouver

Kasun ZA, Liang X, Ferrao RD, Kaplan JA, Clark CT, Neubig ME, et al. The Discovery of GS-1291269: A Neutral Ketohexokinase (KHK) Inhibitor with an Unusual Thietane Amine Functional Group. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02896

BibTeX
@article{Kasun2025,
  author = {Kasun, Zachary A and Liang, Xiaomin and Ferrao, Ryan D and Kaplan, Joshua A and Clark, Christopher T and Neubig, Megan E and Byun, Daniel H and Badal, Shawn S and Sroda, Natalie and Mistry, Tina and Stanley, Nathaniel H and Stevens, Kirk L and Bachman, James L and Lo, Jennifer R and Loyer-Drew, Jennifer and Velasquez, Maile and Hao, Jia and Mwangi, Judy and Stafford, Brian and Jansa, Petr},
  title = {The Discovery of GS-1291269: A Neutral Ketohexokinase (KHK) Inhibitor with an Unusual Thietane Amine Functional Group},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02896}
}
Kostenlos starten →